Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial

When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope that separate trials in other cancers would turn up better results.